Celldex Therapeutics (CLDX) Change in Acquisitions & Divestments (2010 - 2026)

Celldex Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 31.62% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $534.6 million (down 13.69% YoY), while the FY2025 annual figure was $596.3 million, up 18.85% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $133.4 million, up from $111.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $195.0 million in Q1 2025, with the low at $27.8 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $111.5 million (2025), against an average of $107.8 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 562.38% in 2022, while the deepest fall reached 64.3% in 2022.
• Celldex Therapeutics' Change in Acquisitions & Divestments stood at $87.8 million in 2022, then declined by 19.26% to $70.9 million in 2023, then surged by 117.2% to $154.0 million in 2024, then fell by 27.59% to $111.5 million in 2025, then advanced by 19.61% to $133.4 million in 2026.
• Business Quant data shows CLDX's Change in Acquisitions & Divestments at $133.4 million in Q1 2026, $111.5 million in Q4 2025, and $116.9 million in Q3 2025.